University of California at Davis
Welcome,         Profile    Billing    Logout  
 7 Trials 
19 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Li, Tianhong
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

Active, not recruiting
3
151
Europe, US, RoW
Pyrotinib, Irene, Docetaxel, Docetaxel injection
Jiangsu HengRui Medicine Co., Ltd.
Non-squamous NSCLC, HER2 Exon 20 Mutation
06/23
10/23
PRESERVE-003, NCT05671510: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

Active, not recruiting
3
600
Europe, Canada, US, RoW
Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere
OncoC4, Inc., BioNTech SE
Non Small Cell Lung Cancer
06/26
06/27
ALCHEMIST, NCT02201992: Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An Treatment Trial)

Recruiting
3
168
US, RoW
Clinical Observation, Crizotinib, MET tyrosine kinase inhibitor PF-02341066, PF-02341066, PF-2341066, Xalkori, Laboratory Biomarker Analysis
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
05/36
05/36
PRESERVE-001, NCT04140526: Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Recruiting
1/2
733
US, RoW
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody made by OncoC4, Inc., Pembrolizumab, Keytruda, MK3475, Docetaxel, Taxotere, Docefrez
OncoC4, Inc., National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
06/26
12/27
NCT05101356: A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma

Recruiting
1/2
77
US
Antineoplastic Vaccine, cancer treatment vaccine, Cancer Vaccine, Neoplasm Vaccine, Tumor Vaccine, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, Pembrolizumab, KEYTRUDA, MK-3475
Tianhong Li, National Cancer Institute (NCI), LabyRx Immunologic Therapeutics
Advanced Adenocarcinoma, Advanced Malignant Solid Neoplasm, Metastatic Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Adenocarcinoma, Recurrent Malignant Solid Neoplasm
01/26
01/30
DB-1310-O-1001, NCT05785741: A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Recruiting
1/2
1000
US, RoW
DB-1310, Trastuzumab, Osimertinib
DualityBio Inc.
Advanced Solid Tumor
08/26
08/26
ONC-841-002, NCT06352359: Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

Recruiting
1
30
US
ONC-841, Anti-SIGLEC10 antibody
OncoC4, Inc.
Advanced Solid Tumor
09/25
09/27
LEADER, NCT04712877: Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers

Recruiting
N/A
1000
US
ctDNA, tumor NGS, FoundationOne CDx, FoundationOne Liquid
Lung Cancer Mutation Consortium, Lung Cancer Research Foundation
NSCLC
06/25
06/26
Sarkar, Souvik
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
ARGON-2, NCT04378010 / 2019-003876-38: A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

Terminated
2b
98
Europe, Canada, US, RoW
EDP-305 1.5 mg, EDP-305, EDP-305 2 mg, Placebo
Enanta Pharmaceuticals, Inc, Enanta Pharmaceuticals, Inc.
Non-Alcoholic Steatohepatitis
10/21
11/21
NCT05591079: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH

Completed
2
99
US
CS0159 (Linafexor), placebo
Cascade Pharmaceuticals, Inc, Laboratory Corporation of America
Nonalcoholic Steatohepatitis (NASH)
11/23
11/23
LEGEND, NCT05232071: Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

Completed
2
42
Europe, US
IVA337, Lanifibranor, Placebo, Empagliflozin, Jardiance
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
03/24
06/24
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects

Recruiting
2
240
US, RoW
HM15211, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
05/26
11/26
NCT05104853: Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis

Active, not recruiting
1/2
42
US
CNP-104, Placebo
COUR Pharmaceutical Development Company, Inc.
Primary Biliary Cholangitis
01/26
01/26
EXPLORER, NCT04165343: Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on

Completed
N/A
81
US
Positron Emission Tomography (PET) on EXPLORER, PET Scan, Magnetic Resonance Imaging, MRI, Echocardiogram and Electrocardiogram, Echo and EKG or ECG, Blood test, Lab test
University of California, Davis
Non-Alcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
05/23
05/23
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Active, not recruiting
N/A
44467
US
Guardant Health, Inc., Premier Research Group plc
Colorectal Cancer
03/24
12/25
Siefert, Michael
NCT03763643 / 2013-002651-15: PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

Recruiting
1
60
US
Rituximab, Plasmapheresis
University of Minnesota, United States Department of Defense
Focal Segmental Glomerulosclerosis
08/25
12/26
Sageshima, Junichuro
NCT03763643 / 2013-002651-15: PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

Recruiting
1
60
US
Rituximab, Plasmapheresis
University of Minnesota, United States Department of Defense
Focal Segmental Glomerulosclerosis
08/25
12/26

Download Options